anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cardiovascular diseases (CVDs) and neoplasms are leading causes of mortality worldwide.
OBJECTIVE: This study aims to provide a comprehensive analysis of the mortality burden and disability-adjusted life years (DALYs) attributable to CVDs and neoplasms in Western Europe, investigate associated risk factors, and identify regional disparities. Additionally, the study evaluates the effectiveness of the Action Plan for the Prevention and Control of Non-Communicable Diseases (NCDs) in promoting healthier lives in the region.
METHODS: The study collected data on mortality and DALYs due to CVDs and cancers from 24 Western European countries using the Global Burden of Disease Study 2021. The analysis explored age, sex, and country-specific patterns, as well as risk factors contributing to these deaths. Additionally, the study examined time trends by calculating the annual percent change in mortality rates from 1990 to 2021 by region and cause.
RESULTS: In 2021, CVDs and neoplasms accounted for 27.8% and 27.1% of total deaths in Western Europe, with age-standardized death rates of 106.8 and 125.8 per 100,000, respectively. The top two CVDs in this region were ischemic heart disease and stroke, with age-standardized death rates of 47.27 (95% uncertainty interval [UI] 50.42-41.45) and 27.06 (95% UI 29.17-23.00), respectively. Similarly, the top two neoplasms were lung cancer and colorectal cancer, with age-standardized death rates of 26.4 (95% UI 27.69-24.47) and 15.1 (95% UI 16.25-13.53), respectively. Between 1990 and 2021, CVD mortality rates decreased by 61.9%, while cancer rates decreased by 28.27%. Finland had the highest CVD burden (39.5%), and Monaco had the highest rate of cancer-related deaths (34.8%). Gender differences were observed, with males experiencing a higher burden of both CVDs and cancer. Older individuals were also more at risk. Smoking had a stronger impact on CVD mortality and DALYs in males, while a higher Human Development Index was associated with increased cancer deaths and DALYs in females.
CONCLUSIONS: The study findings highlight the substantial burden of NCDs, particularly CVDs and cancer, in Western Europe. This underscores the critical need for targeted interventions and effective implementation of the Action Plan for the Prevention and Control of NCDs to achieve the goal of ensuring healthy lives for all.
The invention relates to analogues of human parathyroid hormone which increase their activities in the recovery of bones and bioaccessibility. The described peptides are derivatives of hPTH-(1-31) which are cycled, for example, by the formation of lactams between or Glu22 and Lys26, or Lys26 and Asp30. Furthermore the natural Lys27 can be substituted either by Leu, or by other hydrophobic residues such as Ile, norleucin, Met, Val, Ala, Trp or Phe. The characteristic thing is that these analogues intensify the abilities for the stimulation of adenilyl cyclase in osteosarcoma cells  and show higher activity in the bone recovery. The analogues also show higher activity and bioaccessibitlity as is shown by their hypotensive effects in rats. The invention also relates to an investigation relating the hypotensive activity to the osteogenic activity. 26 claims
FIELD: pharmaceutical technology. SUBSTANCE: invention relates to a method of extraction of useful substances from plant raw. Plant raw is poured with boiled water, heated and obtained infusion is cooled. Processes of heating and cooling are carried out by treatment of infusion by alternating current. Invention can be used in medicinal, perfume, pharmaceutical and food industries. EFFECT: simplified process. 5 tbl, 5 ex
1397680 Nutrient composition SEPERIC 19 Dec 1973 [18 Jan 1973] 58819/73 Heading A5B A nutrient composition suitable for parenteral administration comprises an aqueous lipid emulsion of pH 7-8 containing (a) an emulsifier, (b) aminoacids in the aqueous phase including essential amino acids and arginine and (c) an acid pH adjuster. The lipid may be soyabean oil or cottonseed oil. The emulsifier may be egg or soyabean lecithin. The essential amino acids may be isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. The pH adjuster may be aspartic acid, malic acid, tartaric acid or citric acid. The composition may also include non-essential aminoacids, e.g. histidine, proline, alanine, serine, asparagine, tyrosine, glycine, cysteine and a glucidic supply, e.g. sorbitol.
The invention comprises (1) novel compounds of Formula I <FORM:1040735/C2/1> where X is hydroxy, alkoxy having up to 6 carbon atoms, or amino, R is hydrogen, halogen, trifluoromethyl, alkyl having up to 8 carbon atoms, a cycloalkyl or cycloalkenyl group having up to 7 carbon atoms an aryl group which may be substituted by halogen, methyl, ethyl, methoxy or ethoxy, analkoxy group having up to 8 carbon atoms, or an aryloxy group, and R1 is any of the atoms or groups described above for R, or R and R1 may together form a cyclic substituent and represent a methylenedioxy, cyclopenta or cyclohexa group, or the group <FORM:1040735/C2/2> may represent an a -naphthyl, b -naphthyl or phenanthyl radical, but when X is hydroxy, R and R1 cannot both be hydrogen, and pharmaceutically acceptable salts of the acid, and (2) the preparation of all compounds of Formula I above by converting a compound of formula <FORM:1040735/C2/3> where Hal represents halogeno, into the corresponding Grignard compound or lithium aryl, which is condensed with a 2,3-epoxypropyl halide, the corresponding 3-aryl-2-hydroxypropyl halide obtained being converted into the corresponding nitrile by treatment with an alkali metal cyanide in a solvent, and the nitrile being converted as required into the desired ester, acid, amide or salt.  The nitrile may be converted to an ester by heating the nitrile in solution in an appropriate alkanol in the presence of an acidic catalyst.  The ester may then be converted to the acid by warming with a slight excess of aqueous alkaline hydroxide solution.  The acid may also be prepared by heating the nitrile with concentrated mineral acid.  The amide is formed by warming the nitrile with hydrogen peroxide solution in the presence of an alkali.  The resulting amide may be hydrolysed to the acid.  Halophenylcycloalkenes may be prepared by treating the cycloalkanone with a halophenyl magnesium bromide and dehydrating the crude carbinol with acetic anhydride in acetic acid. 3-Bromo-4-butoxybiphenyl is prepared by treating the hydroxy compound with butyl bromide.  Therapeutic compositions having anti-inflammatory activity and which may be administered e.g. orally, contain as active ingredient the novel compounds described above.
PURPOSE:To obtain a medicinal preparation realizing long-term stability of preparation containing a depilatory medicine having depilatory effect lowered or lost by oxygen in air. CONSTITUTION:A sheet-like or film-like preparation 2 laminating a substrate for depilation containing a depilatory medicine having depilatory effect lowered and lost by oxygen in air, e.g. thioglycolic acid or its salt, thioglycerin, homocysteine or its ester and having stickiness to skin on a support and an oxygen absorbent 3 obtained by packaging and sealing a deoxidant (e.g. Mg powder or Al powder) with an at least partly air-permeable film or sheet 6 are sealed in a packaging material 4 consisting of a pore-free film or sheet. The preparation 2 consists essentially of 0.5-25wt.% depilatory medicine and an emulsion of a tacky high polymer substance and further contains 5-35wt.% water content based on total amount of the essential components. The substrate for depilation is preferably laminated to the support in a thickness of 100-500mum.
FIELD: medicine, gastroenterology. SUBSTANCE: method deals with fibrogastroduodenoscopy in patients. After gastric and duodenal inspection the state and size of ulcerous defect are estimated, ulcer crater is washed with antiseptic solution. Then endoscopic laser therapy with He-Ne therapeutic laser is conducted for 4-5 areas situated radially around ulcer ranged 3-4 cm at 1-1.5 min exposition followed by ulcerous defect laser therapy at 1-1.5 min exposition. Then ulcerous defect and adjacent wall of stomach or duodenum are sprayed with oxygen foam prepared of dog rose syrup. Endoscopic treatment is carried out daily for the first 4-5 days, then 5-7 times in a day. EFFECT: prophylaxis of possible complications, shortened period of epithelization.
Irinotecan hydrochloride injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1

Care should be exercised in the handling and preparation of infusion solutions prepared from irinotecan hydrochloride injection. The use of gloves is recommended. If a solution of irinotecan hydrochloride contacts the skin, wash the skin immediately and thoroughly with soap and water. If irinotecan hydrochloride contacts the mucous membranes, flush thoroughly with water.
Participants will be randomized to receive single and multiple doses of different dose levels of VX-670. The dose levels will be determined based on the data from Part A.
AIM OF THE STUDY: Biofeedback assisted pelvic floor muscle training is an underutilised nonpharmacological treatment in paediatric urology. We reviewed all patients who underwent a course of treatment at our centre to evaluate its efficacy.
METHODS: All patients who underwent a full cycle of biofeedback in the paediatric urology department from 2016 to 2023 were identified. Demographics and outcomes following treatment were accessed.
RESULTS: 42 patients (28 female) were identified who underwent 8 one-hour sessions on a weekly basis constituted a completed cycle of treatment. Patients were identified for treatment as per local lower urinary tract symptom guidelines and following discussion in a fortnightly urology MDT and including diagnoses of overactive bladder, dysfunctional voiding, and giggle incontinence. Outcomes were measured as successful 29% (continence, normal postvoid residuals, clean intermittent catherization discontinued), partially successful 19% (reduced wetting, abnormal post void residuals, ongoing CIC) and unsuccessful 52% (no change for patient). Age at time of treatment affected likelihood of success: <9 years, 0% success; ≥9 years, 57% [p < 0.05]. There was no significant difference in success for 9-11 years [60%] vs >11 years [56%].
CONCLUSIONS: Biofeedback has shown success with improvement in symptoms in 48% of patients (complete or partial), which increases to 57% success in ≥9 years group. We would advocate its use in these difficult to manage patients with LUTS.
Pregnancy Category X

XENICAL is contraindicated during pregnancy, because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to the obligatory weight gain that occurs in maternal tissues during pregnancy. No embryotoxicity or teratogenicity was seen in animals that received orlistat at doses much higher than the recommended human dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard of maternal weight loss to the fetus.

Animal Data

Reproduction studies were conducted in rats and rabbits at doses up to 800 mg/kg/day. Neither study showed embryotoxicity or teratogenicity. This dose is 23 and 47 times the daily human dose calculated on a body surface area (mg/m 2) basis for rats and rabbits, respectively.
Participants underwent 3 exercise sessions for 60 minutes each. Exercise program was created to improve range of motion and muscle strength. Participants executed active exercise in lying, sitting, and standing positions, isometric exercise, exercise with resistance band. All exercises were repeated 12 times in 3 sets and depending on the capacity of the subject. Breaks between sets 10 sec.
Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
Atypical, low-energy, or low trauma fractures of the femoral shaft have been reported in bisphosphonate-treated patients. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated with bisphosphonates.

Atypical femur fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (e.g. prednisone) at the time of fracture.

  


Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of bisphosphonate therapy should be considered, pending a risk/benefit assessment, on an individual basis.
The invention belongs to the technical field of biology, and relates to a porcine interferon lambda 4 recombinant protein, and a preparation method and application thereof. The amino acid sequence of the porcine interferon lambda 4 (sIFN-lambda 4) recombinant protein is shown in SEQ ID NO. 3. Connecting the sIFN-lambda 4 fragment to a plasmid to obtain a recombinant plasmid, wherein the nucleotide sequence of the sIFN-lambda 4 is shown as SEQ ID NO. 4; and transforming the recombinant plasmid into escherichia coli, then carrying out bacterial liquid culture, adding IPTG (isopropyl-beta-thiogalactoside) for induction, collecting an inclusion body, dissolving and purifying to obtain the recombinant sIFN-lambda 4 protein. The recombinant sIFN-lambda 4 protein can induce the agglutination of gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, salmonella and the like so as to block the agglutination from invading eukaryotic cells, and can inhibit the infection of porcine epidemic diarrhea virus at the cellular and animal organism level. These results indicate that sIFN-. lambda.4 has the dual properties of blocking bacterial infection and resisting viral infection.
The disclosure provides combinations of antibodies and functional fragments, and methods of using antibodies and functional fragments in combination (e.g. each antibody administered individually to a subject sequentially or administered to a subject as a combination composition). Antibodies include IgMs and IgGs. IgMs include combinations of IgMs (e.g., two or more IgMs). IgGs include combinations of IgGs (e.g., two or more IgGs). Combinations include combinations of IgMs (e.g., two or more IgMs), combinations of IgGs (e.g., two or more IgGs) and combinations of IgM and IgG. Methods include administering combinations of IgMs (e.g., two or more IgMs), combinations of IgGs (e.g., two or more IgGs) and combinations of IgM and IgG to a subject.
The apolipoprotein E (APOE) gene has been studied due to its influence on Alzheimer's disease (AD) development and work in an APOE mouse model recently demonstrated impaired respiratory motor plasticity following spinal cord injury (SCI). Individuals with AD often copresent with obstructive sleep apnea (OSA) characterized by cessations in breathing during sleep. Despite the prominence of APOE genotype and sex as factors in AD progression, little is known about the impact of these variables on respiratory control. Ventilation is tightly regulated across many systems, with respiratory rhythm formation occurring in the brainstem but modulated in response to chemoreception. Alterations within these modulatory systems may result in disruptions of appropriate respiratory control and ultimately, disease. Using mice expressing two different humanized APOE alleles, we characterized how sex and the presence of APOE3 or APOE4 influences ventilation during baseline breathing (normoxia) and during respiratory challenges. We show that sex and APOE genotype influence breathing during hypoxic challenge, which may have clinical implications in the context of AD and OSA. In addition, female mice, while responding robustly to hypoxia, were unable to recover to baseline respiratory levels, emphasizing sex differences in disordered breathing.NEW & NOTEWORTHY This study is the first to use whole body plethysmography (WBP) to measure the impact of APOE alleles on breathing under normoxia and during adverse respiratory challenges in a targeted replacement Alzheimer's model. Both sex and genotype were shown to affect breathing under normoxia, hypoxic challenge, and hypoxic-hypercapnic challenge. This work has important implications regarding the impact of genetics on respiratory control as well as applications pertaining to conditions of disordered breathing including sleep apnea and neurotrauma.
This study is a randomized controlled trial of Still Climbin', an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM). Designed to be flexible for use in community settings, this intervention was developed in partnership with community stakeholders who emphasized the need for a community-based program outside of the health care system, and without a specific disease focus. It intends to give Black SMM a safe space to receive support for the whole of their identity and to openly discuss barriers to health care. Participants will be followed for 12 months. The effectiveness of the Still Climbin' intervention will be assessed on health care engagement and receipt of evidence-based preventive care, through surveys administered at multiple points throughout the intervention period. These outcomes will be confirmed with information from medical records. A total of 370 Black participants will be recruited and randomly assign 185 to receive the coping intervention and 185 to a no-treatment control. There will be about 10 groups of about 15 participants each for both intervention and control. Participants will be randomized to an intervention or control group after they complete the baseline survey. Participants will complete four surveys, starting with the baseline survey, and followed by 4-, 8-, and 12-month post-baseline follow-up surveys to assess health care engagement and receipt of evidence-based preventive care (e.g., cancer and diabetes screening, cardiovascular disease prevention, influenza vaccination, HIV prevention), and other topics such as coping strategies, stigma, and discrimination. The intervention is hypothesized to show increased health care engagement and receipt of evidence-based preventive care, in addition to better coping and reduced medical mistrust than the control group.
The experimental group will be taken to scenario-based simulation. The simulation application will be taken to the case suitable for the conflict resolution skills and problem solving skills of the final year students. Before the simulation, students will be informed about the scenario (prebriefing) and expectations will be shared. This stage will take approximately 10 minutes. The student will be given time to solve the conflict for 15 minutes. At the end of the scenario, the student will be taken to the debriefing session.
Nanocrystalline forms of metal oxides, including binary metal oxide, perovskite type metal oxides, and complex metal oxides, including doped metal oxides, are provided. Methods of preparation of the nanocrystals are also provided. The nanocrystals, including uncapped and uncoated metal oxide nanocrystals, can be dispersed in a liquid to provide dispersions that are stable and do not precipitate over a period of time ranging from hours to months. Methods of preparation of the dispersions, and methods of use of the dispersions in forming films, are likewise provided. The films can include an organic, inorganic, or mixed organic/inorganic matrix. The films can be substantially free of all organic materials. The films can be used as coatings, or can be used as dielectric layers in a variety of electronics applications, for example as a dielectric material for an ultracapacitor, which can include a mesoporous material. Or the films can be used as a high-K dielectric in organic field-effect transistors. In various embodiments, a layered gate dielectric can include spin-cast (e.g., 8 nm-diameter) high-K BaTiO 3  nanocrystals and parylene-C for pentacene OFETs.
In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage. Do not use CNS stimulants.
Nephrolithiasis is a common urologic manifestation of Crohn's disease. The purpose of this study was to investigate the clinical characteristics, intestinal oxalate absorption, and risk factors for urinary stone formation in these patients. In total, 27 patients with Crohn's disease and 27 healthy subjects were included in the present study. Anthropometric, clinical, and 24 h urinary parameters were determined, and the [13C2]oxalate absorption test was performed. Among all patients, 18 had undergone ileal resection, 9 of whom had a history of urinary stones. Compared to healthy controls, the urinary excretion values of calcium, magnesium, potassium, sulfate, creatinine, and citrate were significantly lower in patients with Crohn's disease. Intestinal oxalate absorption, the fractional and 24 h urinary oxalate excretion, and the risk of calcium oxalate stone formation were significantly higher in patients with urolithiasis than in patients without urolithiasis or in healthy controls. Regardless of the group, between 83% and 96% of the [13C2]oxalate was detected in the urine within the first 12 h after ingestion. The length of ileum resection correlated significantly with the intestinal absorption and urinary excretion of oxalate. These findings suggest that enteric hyperoxaluria can be attributed to the hyperabsorption of oxalate following extensive ileal resection. Oral supplementation of calcium and magnesium, as well as alkali citrate therapy, should be considered as treatment options for urolithiasis.
The present invention relates to a chewing gum for treating gingival hemorhang, belonging to the traditional Chinese medicine chewing gum field. The chewing gum is mainly composed of purple beautyberry 400-600 weight part; lotus node 200-500 weight part; mint oil 150-350 weight part and eucalyptus oil 150-350 weight part. The groundmass of chewing gum has very strong viscosity. The chewing gum is capable of removing food debris on the tooth surface. The masticatory movement and mechanical stimulus can promote the secretion of saliva and wash mouth surface. The purple beautyberry and lotus node has function of local vasoconstriction and coagulation-time reduction. The chewing gum combines the stypticity of traditional Chinese medicine with the mouth cleaning function and health-car function of the chewing gum, therefore the gingival hemorhang is prevented and treated during chewing the chewing gum.